JAZZ - Jazz Pharmaceuticals plc
161.93 0.00 (0.00%)
After hours: 4:42PM EDT
| Previous Close | 161.01 |
| Open | 161.01 |
| Bid | 138.51 x 800 |
| Ask | 175.87 x 800 |
| Day's Range | 160.15 - 162.33 |
| 52 Week Range | 128.58 - 184.00 |
| Volume | 305,211 |
| Avg. Volume | 512,431 |
| Market Cap | 9.782B |
| Beta | 1.19 |
| PE Ratio (TTM) | 22.84 |
| EPS (TTM) | 7.09 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 195.00 |
- Benzinga•yesterday
The Week Ahead: Alibaba Investor Day, FedEx Earnings, Eventbrite IPO
Below are notable corporate events for the week beginning Sept. 17. Note that this list is not comprehensive and all dates are subject to change. All times are ET. Monday Notable Earnings FedEx Corporation ...
Markit•4 days agoSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ
- PR Newswire•7 days ago
Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch
DUBLIN , Sept. 11, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to provide investors with an overview of the AML treatment landscape ...
- Zacks•12 days ago
Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.•19 days ago
Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) PE Ratio A Signal To Buy For Investors?
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to begin learning about how toRead More...
- PR Newswire•20 days ago
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
DUBLIN , Aug. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Wells ...
Market Realist•22 days agoJazz Pharmaceuticals’ Vyxeos Approved for EU Commercialization
Today, the European Commission (or EC) approved the marketing authorization of Jazz Pharmaceuticals’ (JAZZ) Vyxeos. This authorization covers the treatment of adult individuals with newly diagnosed treatment-associated acute myeloid leukemia with myelodysplasia-related changes (or AML-MRC).
- Zacks•22 days ago
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
- PR Newswire•23 days ago
Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
DUBLIN, Aug. 27, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine.
Markit•25 days agoSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ
- InvestorPlace•28 days ago
5 Low-Cost Biotech Stocks With High Levels of Growth
Biotech stocks have a reputation for risk. Many more established biotech stocks exist that have built drug pipelines and revenue streams. With these pipelines and revenue streams, analysts are able to predict potential profits for years to come.
- InvestorPlace•29 days ago
8 Undervalued Biotech Stocks to Watch
From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) is up double digits since January’s opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.
Markit•last monthSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ
- Thomson Reuters StreetEvents•last month
Edited Transcript of JAZZ earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 Jazz Pharmaceuticals PLC Earnings Call
- American City Business Journals•last month
All that Jazz: Growing pharmaceutical company opens new Philadelphia office
Six years after entering the region with the acquisition of two small drug companies, Jazz Pharmaceuticals has grown to 160 employees here — or “Jazzicians” as the company likes to call its workers. On Monday, the company, after outgrowing its old space, official unveiled its new Center City 46,000-square-foot office on two floors at Commerce Square at 2005 Market St. Jazz President and COO Dan Swisher, said the company plans to add more people in Philadelphia, which is serving as its East Coast headquarters. “I wouldn’t be surprised if we are at 200 by 2020, if not sooner,” Swisher said.
- Investor's Business Daily•last month
These Five 95+ Composite Rating Stocks Are Just Below Buy Points
Five top stocks with IBD Composite Ratings of 95 or higher are closing in on buy points: Urban Outfitters, Veeva Systems, Copart, Automatic Data Processing and Jazz Pharmaceuticals.
- Market Realist•last month
Endo International Has Raised Its Earnings Guidance for 2018
In its Q2 2018 earnings conference call, Endo International (ENDP) raised its 2018 adjusted EBITDA guidance from $1.2 billion–$1.3 billion to $1.27 billion–$1.33 billion. It expects its adjusted gross margin to be 68.5%–69.5%, which is higher than its previously projected range of 67%–68%. Wall Street analysts have projected Endo International’s 2018 adjusted diluted EPS at $2.50, which would be a YoY decline of 34.4%.
Market Realist•last monthAnalyst Ratings for Endo International and Peers in August
In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY (year-over-year) decline of 18.4%. Additionally, the discontinuation of commercialization of certain generic pharmaceutical products in the US market, competitive pressures, and the divestitures of Grupo Farmacéutico Somar and Litha Healthcare Group had negative impacts on Q2 revenues. To know more about the performance of Endo International stock after its Q2 2018 earnings release, be sure to read Why Endo International Stock Soared after Q2 Results.
- Kiplinger•last month
7 Biotech Stocks With Big Upcoming Catalysts
Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018
Markit•last monthSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZ
Market Realist•last monthWall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals
In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.
- Investor's Business Daily•last month
IBD 50 Stock Jazz Pharma Tops Views, But Profit Outlook Light
Jazz Pharmaceuticals on Tuesday reported adjusted income of $3.49 per share on sales of $500 million for its second quarter.
- Investor's Business Daily•last month
Stocks Fall As Trade War Heats Up; This Top Growth Stock Breaks Out
The stock market was mildly lower early Wednesday, as China retaliated with new tariffs on U.S. goods. Michael Kors is breaking out today.
- Market Realist•last month
How Jazz Pharmaceuticals’ Products Performed in the Second Quarter
How Did Jazz Pharmaceuticals Fare in the Second Quarter? Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $356.0 million in the second quarter of 2018, which reflected ~19% year-over-year growth and ~12% sequential growth. Jazz Pharmaceuticals anticipates Xyrem’s net revenues in fiscal 2018 to be in the range of $1.87 million and $1.91 million.
Market Realist•last monthHow Did Jazz Pharmaceuticals Perform in the Second Quarter?
On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.
